BUZZ-GSK falls on slashing annual vaccines forecast

Reuters10-30
BUZZ-GSK falls on slashing annual vaccines forecast

** Shares in GSK GSK.L down as much as 3.5% at 1400p, lowest level since December 2023

** Stock among top losers on FTSE 100 .FTSE index

** British drugmaker cuts 2024 vaccine sales forecast hit by weak demand for its respiratory syncytial virus (RSV) and shingles vaccines

** Now sees FY vaccine sales down by low-single digit percentage vs previous forecast of low-to-mid-single digit percentage growth

** Posts Q3 core EPS of 49.7p, sales of 8.01 bln pounds ($10.41 bln) vs analyst estimates of EPS of 43.6p, sales of about 8 bln pounds

** Up to last close, stock had been largely flat so far this year

(Reporting by Prerna Bedi in Bengaluru)

((Prerna.Bedi@thomsonreuters.com; +91 98052 24616;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment